More on GSK (GSK) Q4: To expand revamp, including restructuring European operations, drug...


More on GSK (GSK) Q4: To expand revamp, including restructuring European operations, drug manufacturing and research in an attempt to save at least £1B a year by 2016, although will take charges of £1.5B. Places Lucozade and Ribena drinks brands under strategic review. Expects core EPS growth of 3-4% CER in 2013, sales growth of 1% CER. Targeting share buybacks of £1-2B this year. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs